PURPOSE OF REVIEW: Oncological treatments are known to induce cardiac toxicity, but the impact of new-onset cancer in patients with pre-existing HF remains unknown. This review focuses on the epidemiology, pathophysiological mechanisms, and clinical implications of HF patients who develop malignancies. RECENT FINDINGS: Novel findings suggest that HF and cancer, beside common risk factors, are deeply linked by shared pathophysiological mechanisms. In particular, HF itself may enhance carcinogenesis by producing pro-inflammatory cytokines, and it has been suggested that neurohormonal activation, commonly associated with the failing heart, might play a pivotal role in promoting neoplastic transformation. The risk of malignancies seems to be higher in HF patients compared to the general population, probably due to shared risk factors and common pathophysiological pathways. Additionally, management of these patients represents a challenge for clinicians, considering that the co-existence of these diseases significantly worsens patients' prognosis and negatively affects therapeutic options for both diseases.
PURPOSE OF REVIEW: Oncological treatments are known to induce cardiac toxicity, but the impact of new-onset cancer in patients with pre-existing HF remains unknown. This review focuses on the epidemiology, pathophysiological mechanisms, and clinical implications of HF patients who develop malignancies. RECENT FINDINGS: Novel findings suggest that HF and cancer, beside common risk factors, are deeply linked by shared pathophysiological mechanisms. In particular, HF itself may enhance carcinogenesis by producing pro-inflammatory cytokines, and it has been suggested that neurohormonal activation, commonly associated with the failing heart, might play a pivotal role in promoting neoplastic transformation. The risk of malignancies seems to be higher in HF patients compared to the general population, probably due to shared risk factors and common pathophysiological pathways. Additionally, management of these patients represents a challenge for clinicians, considering that the co-existence of these diseases significantly worsens patients' prognosis and negatively affects therapeutic options for both diseases.
Authors: Ann Banke; Morten Schou; Lars Videbaek; Jacob E Møller; Christian Torp-Pedersen; Finn Gustafsson; Jordi S Dahl; Lars Køber; Per R Hildebrandt; Gunnar H Gislason Journal: Eur J Heart Fail Date: 2016-01-10 Impact factor: 15.534
Authors: Tal Hasin; Yariv Gerber; Susan A Weston; Ruoxiang Jiang; Jill M Killian; Sheila M Manemann; James R Cerhan; Véronique L Roger Journal: J Am Coll Cardiol Date: 2016-07-19 Impact factor: 24.094
Authors: Pietro Ameri; Marco Canepa; Markus S Anker; Yury Belenkov; Jutta Bergler-Klein; Alain Cohen-Solal; Dimitrios Farmakis; Teresa López-Fernández; Mitja Lainscak; Radek Pudil; Frank Ruschitska; Petar Seferovic; Gerasimos Filippatos; Andrew Coats; Thomas Suter; Stephan Von Haehling; Fortunato Ciardiello; Rudolf A de Boer; Alexander R Lyon; Carlo G Tocchetti Journal: Eur J Heart Fail Date: 2018-02-21 Impact factor: 15.534
Authors: Tal Hasin; Yariv Gerber; Sheila M McNallan; Susan A Weston; Sudhir S Kushwaha; Timothy J Nelson; James R Cerhan; Veronique L Roger Journal: J Am Coll Cardiol Date: 2013-06-27 Impact factor: 24.094
Authors: Rudolf A de Boer; Jean-Sébastien Hulot; Carlo Gabriele Tocchetti; Joseph Pierre Aboumsallem; Pietro Ameri; Stefan D Anker; Johann Bauersachs; Edoardo Bertero; Andrew J S Coats; Jelena Čelutkienė; Ovidiu Chioncel; Pierre Dodion; Thomas Eschenhagen; Dimitrios Farmakis; Antoni Bayes-Genis; Dirk Jäger; Ewa A Jankowska; Richard N Kitsis; Suma H Konety; James Larkin; Lorenz Lehmann; Daniel J Lenihan; Christoph Maack; Javid J Moslehi; Oliver J Müller; Patrycja Nowak-Sliwinska; Massimo Francesco Piepoli; Piotr Ponikowski; Radek Pudil; Peter P Rainer; Frank Ruschitzka; Douglas Sawyer; Petar M Seferovic; Thomas Suter; Thomas Thum; Peter van der Meer; Linda W Van Laake; Stephan von Haehling; Stephane Heymans; Alexander R Lyon; Johannes Backs Journal: Eur J Heart Fail Date: 2020-11-12 Impact factor: 15.534